tiprankstipranks
Advertisement
Advertisement

CLDX Stock Latest News

Celldex 10.345M share Spot Secondary priced at $29.00
The FlyCelldex 10.345M share Spot Secondary priced at $29.00
3h ago
CLDX
Closing Bell Movers: Globalstar spikes on acquisition report
PremiumThe Fly
Closing Bell Movers: Globalstar spikes on acquisition report
6h ago
FC
AMZN
Celldex announces common stock offering, no amount given
PremiumThe Fly
Celldex announces common stock offering, no amount given
9h ago
CLDX
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
PremiumThe Fly
Celldex data shows improvements across six DLQI Domains in barzolvolimab trials
6d ago
CLDX
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Celldex upgraded to Outperform from Peer Perform at Wolfe Research
10d ago
CLDX
Celldex price target raised to $34 from $30 at Goldman Sachs
PremiumThe FlyCelldex price target raised to $34 from $30 at Goldman Sachs
1M ago
CLDX
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
Premium
Ratings
Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts
1M ago
CLDX
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
Premium
The Fly
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
1M ago
CLDX
Celldex price target raised to $44 from $43 at Morgan Stanley
PremiumThe Fly
Celldex price target raised to $44 from $43 at Morgan Stanley
1M ago
CLDX
Celldex price target raised to $68 from $58 at Stifel
PremiumThe Fly
Celldex price target raised to $68 from $58 at Stifel
1M ago
CLDX
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
PremiumRatings
Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating
1M ago
CLDX
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
PremiumRatings
Maintaining Buy on Barzolvolimab: Accelerated Clinical Execution, Best-in-Class Potential, and 2026 Catalyst-Driven Upside
1M ago
CLDX
Celldex reports Q4 EPS ($1.22), consensus ($1.00)
PremiumThe FlyCelldex reports Q4 EPS ($1.22), consensus ($1.00)
1M ago
CLDX
Celldex completes enrollment in Phase 3 studies of barzolvolimab
Premium
The Fly
Celldex completes enrollment in Phase 3 studies of barzolvolimab
1M ago
CLDX
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
Premium
Company Announcements
Celldex’s EvolvE Study Completion Sets Up Key Catalyst in Eosinophilic Esophagitis
2M ago
CLDX
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
PremiumCompany Announcements
Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX
2M ago
CLDX
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
PremiumCompany Announcements
Celldex Advances Barzolvolimab Into Phase 3 for Chronic Inducible Urticaria: What Investors Should Watch
3M ago
CLDX
Celldex price target raised to $24 from $21 at Barclays
PremiumThe Fly
Celldex price target raised to $24 from $21 at Barclays
4M ago
CLDX
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
PremiumCompany Announcements
Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
4M ago
CLDX
Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
PremiumCompany AnnouncementsCelldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
4M ago
CLDX
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
Premium
Market News
These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
4M ago
CLDX
CNTA
Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
Premium
Ratings
Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
4M ago
CLDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >